Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSPNASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$41.99-3.4%$43.02$36.52▼$75.91$3.73B1.772.23 million shs1.19 million shsNTLAIntellia Therapeutics$9.22-4.2%$10.48$8.30▼$28.54$954.43M1.973.29 million shs2.08 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+2.64%-0.80%+10.35%-4.21%-42.24%NTLAIntellia Therapeutics+3.44%+2.78%+0.42%-29.06%-65.37%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics3.1821 of 5 stars4.21.00.00.02.73.30.6NTLAIntellia Therapeutics4.4363 of 5 stars4.31.00.04.71.92.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.48Hold$73.1174.10% UpsideNTLAIntellia Therapeutics 2.63Moderate Buy$37.56307.33% UpsideCurrent Analyst Ratings BreakdownLatest NTLA and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.003/4/2025NTLAIntellia TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$90.00 ➝ $50.002/28/2025NTLAIntellia TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $26.002/28/2025NTLAIntellia TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $14.002/28/2025NTLAIntellia TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$60.00 ➝ $50.002/28/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$91.00 ➝ $68.002/28/2025NTLAIntellia TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$9.002/28/2025NTLAIntellia TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$45.00 ➝ $13.002/19/2025CRSPCRISPR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral2/18/2025CRSPCRISPR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$89.00 ➝ $82.002/14/2025CRSPCRISPR TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderweight ➝ Underweight$30.00 ➝ $32.00(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M102.90N/AN/A$22.52 per share1.86NTLAIntellia Therapeutics$57.88M16.49N/AN/A$11.73 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.37N/AN/AN/A-981.54%-18.46%-15.79%5/14/2025 (Estimated)NTLAIntellia Therapeutics-$481.19M-$5.25N/AN/AN/AN/A-49.34%-40.27%5/8/2025 (Estimated)Latest NTLA and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/11/2025Q4 2024CRSPCRISPR Therapeutics-$1.15-$0.44+$0.71-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A22.0722.07NTLAIntellia TherapeuticsN/A6.736.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.10%NTLAIntellia Therapeutics3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics47385.77 million82.26 millionOptionableNTLAIntellia Therapeutics600103.52 million98.59 millionOptionableNTLA and CRSP HeadlinesRecent News About These CompaniesInvestors who lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class Action - NTLAMarch 13 at 8:45 PM | accessnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLAMarch 13 at 8:36 PM | globenewswire.comShareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLAMarch 13 at 7:00 PM | accessnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLAMarch 13 at 6:35 PM | accessnewswire.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc. (NTLA) ShareholdersMarch 13 at 12:59 PM | globenewswire.comShareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLAMarch 13 at 11:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLAMarch 13 at 10:45 AM | accessnewswire.comClass Action Filed Against Intellia Therapeutics, Inc. (NTLA) - April 14, 2025 Deadline to Join - Contact Levi & KorsinskyMarch 13 at 7:25 AM | accessnewswire.comNTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!March 13 at 7:00 AM | accessnewswire.comLost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law FirmMarch 13 at 5:45 AM | prnewswire.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Down 6.7% - Time to Sell?March 12 at 5:13 PM | marketbeat.comShareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLAMarch 12 at 4:30 PM | accessnewswire.comShareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLAMarch 12 at 4:15 PM | accessnewswire.comNTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMarch 12 at 4:00 PM | globenewswire.comShareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class Action - NTLAMarch 12 at 7:25 AM | accessnewswire.comNTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!March 12 at 7:00 AM | accessnewswire.comShareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreMarch 12 at 5:45 AM | prnewswire.comIntellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLAMarch 11 at 9:30 PM | accessnewswire.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLAMarch 11 at 9:15 PM | accessnewswire.comInvestors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLAMarch 11 at 7:45 PM | accessnewswire.comIntellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)March 11 at 6:31 PM | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTLA and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$41.99 -1.50 (-3.45%) Closing price 04:00 PM EasternExtended Trading$42.26 +0.27 (+0.65%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Intellia Therapeutics NASDAQ:NTLA$9.22 -0.40 (-4.16%) Closing price 04:00 PM EasternExtended Trading$9.33 +0.11 (+1.18%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount? Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Market Overreacts, But Guidewire’s Growth Story Remains Strong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
